Lee Susan J, Paranhos Augusto, Shields M Bruce
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA.
Clin Ophthalmol. 2009;3:81-7. Epub 2009 Jun 2.
To evaluate the benefit of titrating the concentration and exposure time of mitomycin C (MMC) as an adjunct to trabeculectomy.
This report consists of a retrospective study and a review of the literature. In the study, consecutive glaucoma patients were evaluated who underwent trabeculectomy with adjunctive MMC that was titrated for concentration and exposure time, based on patient's risk factors for surgical failure. After minimum follow-up of 6 months, patients were divided into success (intraocular pressure 7-17 mmHg), hypertension (>17 mmHg) and hypotony (<7 mmHg) groups, which were compared with regard to MMC protocol and patient variables. The literature review included reports of trabeculectomy and adjunctive MMC with and without titration.
One hundred and fifty-five eyes of 155 patients were studied. There were no significant differences between the three outcome groups and MMC protocol (p > 0.05). The only significant patient variable was older age in the hypotony group (p = 0.009). The literature is conflicting regarding the value of titrating MMC as an adjunct in trabeculectomy.
The outcome of trabeculectomy with adjunctive MMC appears to represent a complex interaction of patient and surgical variables. While there is some support for a benefit of titrating MMC according to individual patient variables, there is inadequate evidence at the present time to claim superiority for any MMC protocol, with or without titration.
评估作为小梁切除术辅助手段时,滴定丝裂霉素C(MMC)浓度和暴露时间的益处。
本报告包括一项回顾性研究和文献综述。在该研究中,对连续的青光眼患者进行评估,这些患者接受了基于手术失败风险因素进行浓度和暴露时间滴定的MMC辅助小梁切除术。在至少随访6个月后,将患者分为成功组(眼压7 - 17 mmHg)、高血压组(>17 mmHg)和低眼压组(<7 mmHg),并就MMC方案和患者变量进行比较。文献综述包括小梁切除术及有或无滴定的MMC辅助治疗的报告。
研究了155例患者的155只眼。三个结果组与MMC方案之间无显著差异(p > 0.05)。唯一有显著差异的患者变量是低眼压组患者年龄较大(p = 0.009)。关于滴定MMC作为小梁切除术辅助手段的价值,文献观点存在冲突。
MMC辅助小梁切除术的结果似乎代表了患者和手术变量的复杂相互作用。虽然有一些证据支持根据个体患者变量滴定MMC有益,但目前尚无足够证据表明任何MMC方案(无论有无滴定)具有优越性。